Are allogeneic stem cells better than autologous stem cells?

Not in general. The choice depends on the diagnosis, cell type, product or protocol, intended result, donor or patient factors, immune risks and evidence for the exact intervention.

Is a stem cell treatment offered in Japan automatically PMDA-approved?

No. Japan has more than one regulatory framework for regenerative medicine. Patients should ask which pathway applies to the exact intervention and whether PMDA marketing approval covers the specific product and indication.

How long does recovery take after allogeneic stem cell treatment?

Recovery depends on the intervention. After hematopoietic cell transplantation, immune recovery can take many months. A regenerative cell procedure should use the follow-up schedule and endpoint from the exact disease-specific protocol.

How much do allogeneic stem cells cost in Japan?

There is no responsible universal price. A useful quote should identify the exact product or protocol and separate medical review, tests, cell product or processing, administration, related care, follow-up, rehabilitation, translation and coordination.

Making sense of the choice

Autologous vs. Allogeneic Stem Cells

Q: What is the survival rate after allogeneic stem cell treatment?

There is no single allogeneic stem cell survival rate. In hematopoietic transplantation, survival depends on disease, disease status, age, comorbidities, donor, graft source and conditioning. Many regenerative cell therapies use function, symptoms, healing or organ-specific outcomes instead of survival as the main efficacy endpoint.

First identify which type of stem cell care you are actually considering. For blood cancers and marrow disorders, allogeneic stem cells usually mean donor hematopoietic transplantation. For regenerative uses, the proposal may instead involve donor-derived mesenchymal or other cells. Their evidence, risks, recovery and costs are not interchangeable.

HCT or regenerative cell therapy Disease-specific evidence Current Japan status Measured follow-up Full cost

Find Out What Fits Your Situation Talk Through Your Specific Case

A licensed physician needs to review your diagnosis, records and current health status before any treatment decision can be made.

Illustrative placeholder image. It is not presented as a treatment result or proof of benefit.

Here’s what the difference means in practice

Autologous and allogeneic are two sources, not two levels of quality.

A donor-derived product may be ready without harvesting your tissue. A self-derived product avoids donor mismatch. Neither point proves that the treatment will work for your diagnosis.

Your own cells

Autologous

SourceBone marrow, blood, fat or another tissue from the patient, depending on the protocol.

PreparationRequires patient-specific collection, testing and processing. Culture may add time when expansion is part of the protocol.

Immune issueDonor mismatch is avoided, but sterility, cell quality, harvest risk and treatment-specific adverse effects still matter.

Main variableAge, previous treatment, disease and source-tissue quality can affect the starting material.

Donor-derived cells

Allogeneic

SourceCells come from a screened donor or a donor-derived manufactured product.

PreparationBanked or manufactured cells can remove the need for a personal harvest, depending on the product.

Immune issueHLA matching is central in donor hematopoietic transplantation. Other donor-derived cell products have different immune requirements.

Main variableDonor screening, lot consistency, identity, viability, sterility, potency and traceability become central quality questions.

It’s easy to confuse two very different things. Allogeneic hematopoietic stem cell transplantation for leukemia or marrow disorders is not the same procedure as a donor-derived mesenchymal stem cell product used in regenerative medicine.

Numbers are useful only when the diagnosis, cell product, route and patient population match the question you are asking.

Numbers you can check yourself

Use study numbers with the exact disease and product attached.

Don’t treat these numbers as a general “stem cell success rate.” They show how different the evidence can be between one product and the next, or one indication and another.

25 patientsPMDA reviewed a Japanese study of TEMCELL in severe Grade III or IV acute GVHD after allogeneic hematopoietic transplantation when systemic steroids had not worked. PMDA

48.0%12 of 25 patients achieved a complete response lasting at least 28 days. Survival was 60.0% at Day 180 and 52.0% at Week 52. The study was small and did not use a contemporary randomized control, so these figures should not be treated as a personal forecast. PMDA

8 infusionsThe reviewed TEMCELL regimen was 2 × 10⁶ cells/kg twice weekly for four weeks, at least three days apart, with additional weekly dosing allowed in defined response situations. This dose belongs to that product and indication only. PMDA

212 patientsIn the original ADMIRE-CD study of donor-derived darvadstrocel for selected complex Crohn’s perianal fistulas, combined remission at Week 24 was 51.5% versus 35.6% with control; at Week 52 it was 56.3% versus 38.6%. Peer-reviewed trial

568 patientsThe later randomized ADMIRE-CD II study did not meet its primary endpoint: combined remission at Week 24 was 48.8% with darvadstrocel versus 46.3% with placebo (P = .571). Secondary endpoints also showed no statistically significant differences. Takeda then moved to withdraw Alofisel’s EU authorization in December 2024. 2026 trial Authorization update

Japan status check: PMDA states that Japan has both the Act on the Safety of Regenerative Medicine and the PMD Act, while the PMD Act governs commercialization of regenerative medical products. A cell therapy being offered in Japan is therefore not, by itself, proof that the exact product and indication hold PMDA marketing approval. PMDA framework

What it boils down to for your condition

The useful question is not “Do stem cells work?” It is “What evidence exists for my exact disease?”

Each disease calls for a different cell type and a different way of measuring results. Start with the row closest to your diagnosis, then take that to your next medical review.

Leukemia, lymphoma, marrow failureEstablished transplant fieldAutologous or allogeneic hematopoietic stem cell transplantation may be standard care for selected diagnoses. The decision is based on disease subtype, remission status, prior therapy, age, organ function, donor options, relapse risk and transplant risk. MSC treatment data should not be used to predict these outcomes.

Acute GVHD after transplantProduct-specific evidenceTEMCELL is a Japan example of donor-derived bone-marrow MSCs for a defined steroid-refractory acute GVHD setting. The PMDA study data above apply to this narrow population, not to unrelated inflammatory or neurological diseases.

Complex Crohn’s perianal fistulasEvidence changed over timeDarvadstrocel showed a benefit in the first Phase 3 study, but the larger confirmatory Phase 3 study failed its primary endpoint. A patient should check the latest regulatory and availability status rather than relying on the original approval story alone.

Traumatic spinal cord injuryAutologous Japan exampleSTEMIRAC is an autologous, not allogeneic, bone-marrow-derived product with a defined Japan regulatory history. It cannot be used as proof that a donor-derived MSC infusion is effective for chronic spinal cord injury.

Knee osteoarthritis and chronic painProtocol-specificAsk for controlled human data for the exact cell source, preparation and route. A useful result should include pain and function, adverse events and durability; claims of “cartilage regeneration” need objective evidence rather than symptom reports alone.

Stroke and neurological diseaseOften investigationalAsk whether there is a randomized human trial, when cells were given after the event, what neurological or functional scale was used, and whether the change was large enough to matter in daily life. Do not use transplant survival data to judge a neurological cell therapy.

DiabetesOften investigationalUseful endpoints include HbA1c, insulin requirement, C-peptide when relevant, severe hypoglycemia and safety. “Regeneration” by itself is not an outcome a patient can verify.

Heart, liver or kidney diseaseDiagnosis-specific researchAsk for organ-specific outcomes such as cardiac function, kidney function, liver function, hospital admission or other accepted clinical measures. Evidence from one organ cannot be transferred to another.

Anti-aging and broad wellness claimsHigh cautionOne cell product claiming to improve many unrelated diseases, aging, immunity and organ function should trigger a deeper evidence check. Ask for the exact indication, trial, endpoint, adverse-event data and current regulatory pathway before paying.

Let’s Look at What You Have I Need a Practical Next Step

Getting the right records together

Send records that can confirm the diagnosis and change the decision.

A request saying only “I want allogeneic stem cells” cannot answer eligibility, expected benefit or risk. The review has to start with measurable clinical information.

DiagnosisExact disease name, subtype, stage or severity, date of diagnosis and the specialist’s latest assessment.

Objective testsRecent imaging, pathology, blood tests, neurological or functional scores, and disease-specific reports.

Current statusWhat you can and cannot do now, current symptoms, recent changes and whether the condition is stable or progressing.

Past careSurgery, medication, chemotherapy, radiation, rehabilitation, transplant or previous cell therapy, including the response and major adverse events.

Safety informationCurrent medicines, allergies, infections, previous cancer, clotting or bleeding issues and major heart, lung, liver or kidney problems.

Your targetState one or two outcomes that would matter: disease control, mobility, pain and function, neurological change, fistula healing, reduced medication or another measurable result.

Here’s why this makes a real difference: the same diagnosis can produce a different answer when disease stage, previous treatment, infection status, organ function or the intended endpoint changes. These are review factors, not a universal eligibility checklist.

A complete record set lets the medical discussion move from general claims to diagnosis-specific questions.

Risk and survival data

Use transplant numbers only for transplant, and product data only for that product.

Allogeneic hematopoietic transplant

This is the donor transplant used for selected blood and marrow diseases.

Conditioning treatment, infection, graft-versus-host disease, graft failure, organ toxicity and relapse are major parts of the risk discussion.

NMDP states that graft failure occurs in approximately 5% of allogeneic transplants, although the rate varies by graft source and patient factors. NMDP

HLA matching and donor choice matter, but modern protocols can also use selected mismatched donors.

Donor-derived MSC or other cell product

The safety questions are different from donor hematopoietic transplantation.

Donor eligibility, infectious-disease screening, sterility, identity, viability, potency and traceability should be defined for the exact product.

Ask for adverse events from the exact route and dose. Local injection, intravenous infusion and surgical administration do not have the same risk profile.

Do not assume that “immune privileged” means “no immune risk.” Ask what immune reactions were actually measured in human studies.

One study, one populationNot a personal survival forecast

A current transplant study shows why the protocol has to stay attached to the percentage.

In the NMDP ACCESS study of adult mismatched unrelated-donor peripheral blood stem cell transplantation using post-transplant cyclophosphamide, one-year outcomes differed by conditioning intensity.

83.8%1-year overall survival with myeloablative conditioning

78.6%1-year overall survival with reduced-intensity or nonmyeloablative conditioning

8% / 10%Grade 3–4 acute GVHD in the two conditioning groups

19.6% / 14.3%Chronic GVHD, all grades, in the two conditioning groups

How to read these numbers: they are from a specific mismatched unrelated-donor HCT protocol, not a general allogeneic stem cell survival rate and not an outcome estimate for MSC-based regenerative treatment. Your diagnosis, disease status, age, comorbidities, donor, graft source and conditioning can materially change risk. NMDP ACCESS results

Know the exact protocol or product name? Send it over with your diagnosis and current records.

Ask Us Directly

The follow-up schedule should match the intervention. Transplant immune recovery and regenerative-treatment outcome checks are different.

What recovery is really like

Ask what should change, when it will be checked and what happens if it does not change.

There’s no such thing as a universal “stem cell recovery time.” After allogeneic HCT, immune recovery can take months. For regenerative cell therapy, the timeline should come from the disease-specific study and its endpoints.

BaselineRecord the same disease-specific measures that will be used after care: imaging, laboratory values, pain and function, neurological scores, fistula status or another accepted endpoint.

About 1 monthFor HCT, NMDP lists average full recovery of neutrophils and phagocytes at about one month. Early infection and transplant complications still require close monitoring. NMDP

6–12 monthsNMDP lists average T-cell recovery in this range after HCT. This is an immune-recovery estimate, not a timeline for improvement from an MSC procedure.

12–24 monthsNMDP lists average B-cell recovery in this range after HCT. Long-term follow-up can also include GVHD, infection, relapse and organ effects when relevant.

Regenerative careUse protocol-defined follow-up dates. A claim such as “you should feel better in a few weeks” is not enough unless the exact study used the same disease, cell product, route, dose and outcome measure.

Cost and timing

A useful quote names the exact product or protocol and every major charge.

There is no evidence-based universal price for “allogeneic stem cells in Japan.” HCT, a licensed cell product and a regenerative-medicine protocol can have completely different dose, setting, monitoring and follow-up requirements.

The TEMCELL example above also shows why a “price per infusion” can be misleading: its reviewed protocol used weight-based dosing and eight initial infusions, while darvadstrocel used a one-time local product dose for a different disease. Cost should follow the exact protocol, not the cell-source label.

Get a Clear Cost Breakdown Check What Is Included

Medical reviewSpecialist review, consultation and any additional opinion required before an option can be discussed.

Pre-treatment testsLaboratory testing, imaging, infection screening, donor or HLA work when relevant, and disease-specific assessments.

Cell componentExact product, number of units or doses, or autologous collection, processing, culture, release testing and storage when applicable.

AdministrationInfusion, injection, local procedure, surgery, inpatient care or another route defined by the protocol.

Related careConditioning, medication, rehabilitation, monitoring, management of complications or other protocol-related care when relevant.

Follow-upRepeat tests, outcome review and the plan if the expected endpoint is not reached.

International supportMedical document organization, translation and coordination charges should be shown separately from medical charges.

How we help you sort through it

We help turn a general stem cell inquiry into specific questions a physician can answer.

For international patients, finding the phrase “stem cells” isn’t the hard part. The real work is matching your diagnosis to the right intervention, checking the current evidence, pulling together the records you need, and understanding what it’ll cost and what follow-up requires.

Build a clear case summary

We organize diagnosis, reports, previous care, medicines, current function and the result you want to discuss.

Identify the exact proposal

We help clarify whether the discussion concerns HCT, an allogeneic MSC product, another cell type or an autologous protocol, including source, route and dose when available.

Separate old evidence from current evidence

We help organize the questions around the newest relevant study, current Japan regulatory status, major limitations and whether the evidence actually matches your diagnosis.

Clarify cost and schedule

We help request an itemized explanation of the steps, tests, cell-related charges, follow-up and timing instead of relying on a single headline price.

Support bilingual communication

We support medical document and discussion translation so questions about evidence, risk, alternatives, expected outcomes and follow-up are not lost between languages.

Prepare My Information Ask About Next Steps

Our role is information organization, coordination and communication support. Diagnosis and medical decisions remain with licensed physicians.

Three things to nail down first

Three things should be written down, not left as general claims.

You should be able to identify what will be used, why the evidence applies to you and how safety and follow-up will be handled.

Exact intervention

Cell type, tissue source, donor or self-derived status, product or protocol name, route, dose and whether it is PMDA-approved for that indication, another Japan regulatory pathway, or a clinical study.

Current evidence

Newest relevant human study, number of patients, comparator, main endpoint, size of benefit, important safety findings and whether later studies confirmed or contradicted the first result.

Safety and follow-up

Known adverse events, monitoring, emergency plan, planned reassessment dates, the objective measure of benefit and what happens if there is no meaningful improvement.

Broad-claim warning: the U.S. FDA stated in May 2026 that it continues to receive complaints and adverse-event reports, including deaths, involving certain unapproved human cell or tissue products. This does not describe every cell therapy, but it is a reason to verify the exact regulatory status and evidence before accepting claims across many unrelated diseases. FDA 2026 warning

Medical and regulatory references

The figures above are tied to named sources and populations.

Last checked 11 August 2026. Regulatory status, product availability, indications and clinical evidence can change. Recheck the exact product or protocol before making a medical, travel or financial decision.

PMDA — Regenerative Medical ProductsCurrent Japan regulatory framework, including the PMD Act, the Act on the Safety of Regenerative Medicine and links to approved regenerative medical products. PMDA — TEMCELL HS Inj. Review ReportJapanese steroid-refractory acute GVHD study, response and survival data, dose schedule and safety review for donor-derived bone-marrow MSCs. PubMed — ADMIRE-CD Phase 3 Follow-upPeer-reviewed 212-patient randomized study with the Week 24 and Week 52 combined-remission figures used above. Takeda — Alofisel Update, December 2024Confirmatory-study context, lack of statistically significant secondary endpoint differences and the decision to pursue voluntary EU authorization withdrawal. PMDA — STEMIRAC Review ReportJapan review for the autologous bone-marrow-derived MSC product used here only as a diagnosis- and product-specific comparison with allogeneic approaches. PubMed — ADMIRE-CD II Phase 3 Randomized TrialPeer-reviewed 2026 publication confirming that the 568-patient trial did not meet the Week 24 primary endpoint and found no new safety signal. NMDP — ACCESS Trial ResultsOne-year survival and acute/chronic GVHD data from a specific adult mismatched unrelated-donor HCT protocol using post-transplant cyclophosphamide. NMDP — Post-Transplant CareAllogeneic HCT graft-failure estimate and average immune-recovery times for neutrophils/phagocytes, T cells and B cells. National Cancer Institute — Stem Cell Transplants for CancerPatient information distinguishing autologous and allogeneic hematopoietic transplantation and major transplant risks. U.S. FDA — Patient and Consumer Warning, May 2026Current warning about serious risks and reported adverse events involving certain unapproved human cell and tissue products.

Time to get personal

Get clarity before you choose a cell source.

Send your diagnosis, recent reports, previous care and the result you want to discuss. We can help organize the information, separate HCT from regenerative cell therapy, identify the questions that need evidence, and support the next bilingual discussion in Japan.

WhatsApp: +81-8070161366 LINE: +81-8075357788

This is educational information. It doesn’t diagnose disease, recommend a specific product, guarantee eligibility or predict your individual outcome. Please don’t delay or stop standard medical care based on anything you’ve read here.